• 한국임상수의학회지
• /
• 제19권3호
• /
• pp.342-349
• /
• 2002

Vitamin D is one of important factors involved in the regulation of bone metabolism. In osteoporosis, the therapeutic effect of vitamin D on the healing process has still been controversial. To conform the effect of $1{\alpha}$, 25 dihydroxy-vitamin $D_3$ on osteoporosis, the change of serum calcium, serum phosphorus, serum alkaline phosphatase, bone mineral density and bone mineral content of osteoporotic tibia were examined comparatively in normal control group(positive control), CFA control(negative control), CFA+$1{\alpha}$, 25 dihydroxy-vitamin $D_3$ 0.01 ug/kg group and CFA+$1{\alpha}$, 25 dihydroxy-vitamin $D_3$ 0.1 ug/kg group after osteoporosis was induced by single injection of complete Freund's adjuvant(CFA) in rats. In change of serum calcium. the significantly increased value was shown on 2nd and 5th week(P< 0.05) after treatment in $1{\alpha}$, 25 dihydroxy-vitamin D$_3$ 0.01 ug/kg group and on 3rd week(P<0.05) after treatment in $1{\alpha}$, 25 dihydroxy-vitamin $D_3$ 0.1 ug/kg group than CFA control. In change of serum phosphorus, the significantly increased value was shown on 2nd week(P<0.05) after treatment in $1{\alpha}$, 25 dihydroxy-vitamin $D_3$ 0.01 ug/kg group and on 3rd and 4th week(P<0.05) after treatment in $1{\alpha}$, ,25 dihydroxy-vitamin $D_3$ 0.1 ug/kg group than CFA control. The value of bone mineral density and bone mineral content of tibia was increased in both $1{\alpha}$,25 dihydroxy-vitamin $D_3$ 0.01 ug/kg group and $1{\alpha}$, 25 dihydroxy-vitamin $D_3$ 0.1 ug/kg group than CFA control, and the increase rate of that was higher in $1{\alpha}$, 25 dihydroxy-vitamin $D_3$ 0.1 ug/kg group than $1{\alpha}$, 25 dihydroxy-vitamin $D_3$ 0.01 ug/kg group. Considering above findings collectively, it was considered that $1{\alpha}$, 25 dihydroxy-vitamin $D_3$ was effective in preventing the complete Freund's adjuvant-induced osteoporotic decrease of bone mass.

• 대한치주과학회:학술대회논문집
• /
• 대한치주과학회 1998년도 제38회 종합학술대회 연제초록
• /
• pp.38-38
• /
• 1998

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권6호
• /
• pp.2227-2230
• /
• 2015

Background: Prostate cancer (PCa) is one of the most commonly diagnosed neoplasms and the second leading cause of cancer death in men in the Western world. Vitamin D (1,25dihydroxy vitamin D) is linked to many biological processes that influence oncogenesis but data on relations between its genetic variants and cancer risk have been inconsistent. The aim of this study was to determine associations between a vitamin D genetic polymorphism and 25-hydroxyvitamin D [25(OH)D] levels and prostate cancer. Materials and Methods: Genomic DNA was extracted from 124 Jordanian prostate cancer patients and 100 healthy volunteers. Ethical approval was granted from the ethical committee at Hashemite University and written consent was given by all patients. PCR was used to amplify the vitamin D receptor Fok1 polymorphism fragment. 25(OH)D serum levels were measured by competitive immunoassay. Results: All genotypes were in Hardy-Weinberg equilibrium. Genotype frequency for Fok1 genotypes FF, Ff and ff was 30.7%, 61.3% and 8.06%, for prostate cancer patients, while frequencies for the control group was 28.0%, 66.0% and 6.0%, respectively, with no significant differences. Vitamin D serum level was significantly lower in prostate cancer patients (mean 7.7 ng/ml) compared to the control group (21.8 ng/ml). No significant association was noted between 25(OH)D and VDR Fok1 gene polymorphism among Jordanians overall, but significant associations were evident among prostate cancer patients (FF, Ff and ff : 25(OH)D levels of 6.2, 8.2 and 9.9) and controls (19.0, 22.5 and 26.3, respectively). An inverse association was noted between 25(OH)D serum level less than 10ng/ml and prostate cancer risk (OR 35.5 and 95% CI 14.3- 88.0). Conclusions: There is strong inverse association between 25(OH)D serum level less than 10ng/ml level and prostate cancer risk.

• Journal of Animal Science and Technology
• /
• 제45권3호
• /
• pp.455-462
• /
• 2003

이 연구는 소 비육후기에 칼슘제(석회석)를 첨가하지 않은 사료의 급여가 성장율, 근내지방도 및 혈청 1,25-dihydroxy vitamin $D_3$ ($1,25(OH)_2D_3$) 함량에 미치는 영향을 구명하기 위하여 수행되었다. 거세 한우 24두(20${\sim}$24개월령)를 12두씩 대조구(석회석 2.5% 함유 농후사료)와 칼슘제 무첨가구(석회석 0%)로 배치하여 223일 동안 사료(농후사료 및 오차드그라스 건초)와 물을 무제한 급여하였고, 사양시험이 완료된 후 도축하여 육질을 평가하였다. 혈청 $Ca^{2+}$, Ca 및 P 함량에는 처리 간 차이가 없었으나 (P>0.05), 1,25(OH)2D3 함량은 시험 시작 후 2 또는 6개월째 모두 칼슘제 무첨가구가 대조구보다 (각각 78.3 vs 51.7 또는 80.3 vs 51.1 pg/mL) 높았다 (P<0.01). 칼슘제를 첨가하지 않은 사료를 급여한 비육우가 대조구보다 농후사료 섭취량은 증가하고 건초 섭취량은 감소하는 경향을 보였다. 일당증체량은 대조구보다 칼슘제 무첨가구에서 높았다(P<0.01). 등심단면적(82.8 vs 77.2 $cm^2$), 근내지방도(5.1 vs 2.2) 및 지방 함량(10.2 vs 6.7%)이 칼슘제 무첨가구가 대조구보다 높았고 (P<0.05), 수분 함량(67.6 vs 70.4%)은 낮았다 (P < 0.05). 등심 육색, pH 및 보수력에서는 처리 간 차이가 없었으나 전단력에서는 칼슘제 무첨가구에서 (2.9 vs 3.2 kg/1.27-cm diameter core) 약간 낮게 (P = 0.08) 나타났다. 관능평가에서는 칼슘제 무첨가구가 대조구보다 연도 (4.9 vs 4.5) 및 향미(4.9 vs 4.6)가 약간 개선되었으나 (P<0.05) 다즙성에서는 처리간 차이가 없었다 (P>0.05). 본 연구결과는 비육후기에 칼슘제(석회석)를 첨가하지 않은 사료의 급여는 에너지 섭취의 증가 또는 1,25$(OH)_2D_3$의 합성 촉진을 통하여, 근내지방합성이 증가되어 성장율 및 근내지방도를 개선한다는 것을 제시하였다.

• 대한치과교정학회지
• /
• 제25권3호
• /
• pp.333-339
• /
• 1995

[ $1,25-(OH)_2D_3$ ]가 치주인대세포의 증식에 미치는 영향과 조골세포 기능을 나타내는 지표이며 골의 석회화 과정에 관여하는 alkaline phosphatase의 활성도에 미치는 영향을 관찰하여 아직 확실히 밝혀져 있지 않은 치주인대조직에 대한 $1,25-(OH)_2D_3$의 생물학적 기능을 알아보고자 교정 치료 목적으로 발거된 치아로부터 치주인대세포를 배양하였다. $1,25-(OH)_2D_3$를 첨가하여 24시간 후 [${^3}H$]thymidine으로 DNA를 표지하여 세포의 증식을 관찰하였으며 $1,25-(OH)_2D_3$가 치주인대세포에서 조골세포의 표지효소인 alkaline phosphatase의 활성도에 미치는 영향을 24시간 또는 6일간 $1,25-(OH)_2D_3$ 처리후 측정한 결과 100nM농도의 $1,25-(OH)_2D_3$은 치주인대세포의 증식을 유의하게 증가시켰으며 10nM에서는 차이를 보이지 않았다. $1,25-(OH)_2D_3$을 24시간 첨가시 10nM에서는 ALP활성도는 $80.8\pm31.4$nmol로 서 대조군 $38.5\pm5.3$nmol에 비해 유의하게 증가하였으며 또한 $1,25-(OH)_2D_3$을 6일동안 첨가하였을때에도 10nM에서 $106.7\pm23.0$nmol로 대조군 $29.3\pm1.0$nmol에 비해 유의하게 증가되었다. 이상의 결과를 종합하면 $1,25-(OH)_2D_3$이 치주인대세포의 증식 및 세포기능을 시사하는 결과로 사료된다.

• Journal of Periodontal and Implant Science
• /
• 제30권1호
• /
• pp.39-52
• /
• 2000

Polypeptide growth factor belong to a class of potent biologic mediator which regulate cell differentiation, proliferation, migration and metabolism. 1,25-dihydroxyvitamin $D_3$ decrease cell proliferation, and stimulate alkaline phosphatase activity which express in osteoblast during cell differentiation period. IGF-I is known to stimulate cell proliferation and differentiation too. 1,25-dihydroxyvitamin $D_3$ is known to increase IGF-I binding sites and IGF binding protein which inhibite the effect of IGF. The purpose of this study is to evaluate potential role of IGF-I as mediator that control the action of 1,25-dihydroxyvitamin $D_3$. MC3T3-E1 cell were seeded $5{\times}10^5/ml$ at 100mm culture plate in ${\alpha}-MEM$ containing 10% fetal bovine serum. After 48 hour incubation period, medium were changed ${\alpha}-MEM$ containing 5% fetal bovine serum. After 24 hours, $10^{-9}M$ 1,25-dihydroxyvitamin $D_3$ added. Total mRNA was extracted at 0, 6, 24, 48, 72 hour. PRPCR method was programed for the detection of IGF-I mRNA. In the both groups of 1,25-dihydroxy vitamin $D_3$ treated and control, alternative splicing form of IGF-I, IGF-IA and IGF-IB were expressed. In the 1,25-dihydroxyvitamin $D_3$ treated group, IGF-I mRNA expression was matained until 24 hour, there after expression was decresed. MC3T3-E1 cell were seeded $2.5{\times}10^4/ml$ at 24well plate in ${\alpha}-MEM$ containing 10% fetal bovine serum. After 48 hour incubation period, medium were changed ${\alpha}-MEM$ containing 3% fetal bovine serum. After 24 hours, $10^{-9}M$ 1,25-dihydroxyvitamin $D_3$ and 10 ng/ml IGF-I were added separately or together. Cell were cultured for 1 and 3 days, $2{\mu}Ci/ml\;[^3H]$ -thymidine was added for the last 24h of culture of each days. ${[^3H]}$-thymidine incorporation in to DNA was measured and expressed counter per minute(CPM). DNA synthetic activity was significantly decreased by 1,25-dihydroxyvitamin $D_3$ both at 1 day and 3 day, and in the combination group of 1,25-dihydroxyvitamin $D_3$ and IGF-I, DNA synthetic activity was also decreased both at 1 day and 3 days. IGF-I did not affect the DNA synthetic activity compared to control group both at 1 day and 3 day. From the above results, 1,25-dihydroxyvitamin $D_3$ was potent inhibitor of cell proliferaton in MC3T3-E1 cells. It assumed that the effect of 1,25-dihydroxyvitamin $D_3$ on osteoblast proliferation may be mediated in part by decreased level of IGF-I.

• International Journal of Oral Biology
• /
• 제38권3호
• /
• pp.127-134
• /
• 2013

Xylitol is a sugar alcohol with a variety of functions including bactericidal and anticariogenic effects. However, the cellular mechanisms underlying the role of xylitol in bone metabolism are not yet clarified. In our present study, we exploited the physiological role of xylitol on osteoclast differentiation in a co-culture system of osteoblastic and RAW 264.7 cells. Xylitol treatment of these co-cultures reduced the number of tartrate-resistant acid phosphatase (TRAP)-positive multinucleated cells induced by 10 nM $1{\alpha},25(OH)_2D_3$ in a dose-dependent manner. A cell viability test revealed no marked cellular damage by up to 100 mM of xylitol. Exposure of osteoblastic cells to xylitol decreased RANKL, but not OPG, mRNA expression in the presence of $10^{-8}M$ $1{\alpha},25(OH)_2D_3$ in a dose-dependent manner. Furthermore, bone resorption activity, assessed on bone slices in the coculture system, was found to be dramatically decreased with increasing xylitol concentrations. RANKL and OPG proteins were assayed by ELISA and the soluble RANKL (sRANKL) concentration was decreased with an increased xylitol concentration. In contrast, OPG was unaltered by any xylitol concentration in this assay. These results indicate that xylitol inhibits $1{\alpha},25(OH)_2D_3$-induced osteoclastogenesis by reducing the sRANKL/OPG expression ratio in osteoblastic cells.

• International Journal of Oral Biology
• /
• 제32권4호
• /
• pp.143-151
• /
• 2007

This study was conducted to investigate the preventing effects of OPB (Rehmannia glutinosa Libosch and Eleutherococcus senticosus Max extracts) and combined OPB/Calcium therapy on bone loss in ovariectomized rats. Sixty Sprague Dawley rats of 12-week-old were divided into eight groups: OVX (ovariectomized), OPBL (OPB 50 mg/kg), OPBM (OPB100 mg/kg), OPBH (OPB 200 mg/kg), OPBL/CAL(OPBL+CAL), OPBM/CAL (OPBM+CAL), OPBH/CAL (OPBH+CAL) and CAL (Calcium citrate 88.33 mg/kg+1$\alpha$, 25-dihydroxy-vitamin $D_3$ 33.33 IU/kg). Bone mineral density (BMD), bone mineral content (BMC), bone strength indices and cortical thickness were analyzed by peripheral quantitative computerized tomography (pQCT). pQCT scanning showed that OVX induced a significant decrease in trabecular bone mineral density and bone mineral content in the proximal tibia $(-36.4\pm2.4%,\;-21.8\pm12.7%)$. These decreases were significantly prevented by the administration of OPBM and OPBM/CAL. Cortical BMD and BMC of tibia were slightly enhanced by OPB and OPB/CAL. However there was no significant difference between OVX and OPB, OPB/CAL treated group. Bone strength indices and cortical thickness were not significantly different. Our results suggest that OPB and combined OPB/Calcium therapy are effective in preventing the development of bone loss induced by ovariectomy in rats.